Rylomine impresses in Ph III pain trial

Massachusetts, USA-based drugmaker Jevelin Pharmaceuticals says that its drug candidate Rylomine (intranasal morphine) met its primary efficacy endpoint, a reduction of the sum of pain intensity difference (SPID) scores, in a trial examining it as a treatment for post-operative pain.

The Phase III trial recruited patients suffering moderate-to-severe pain following elective orthopedic surgery, randomizing them to receive either 7.5mg of Rylomine every hour as needed, 15mg of the drug every three hours as required, intravenous morphine every three hours as needed, or placebo.

Early analysis of the results indicate that subjects who received Rylomine had significantly improved SPID scores, over 24 hours, compared with those in the placebo group. Javelin said that it would make full data available in due course.